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Background: We aimed to evaluate the accuracy and acceptability of a short screening test battery for mild
neurocognitive deficits.
Methods: HIV-infected individuals with a suppressed viral load were examined at the University Hospital Basel with
a screening test consisting of a questionnaire and selected cognitive tests, administered by trained nurses, followed
by an in-depth neuropsychological examination. Test acceptance was evaluated with a questionnaire.
Results: 30 patients were included in this study (median age of 52.5 years (interquartile range (IQR) 47–64), prior
AIDS-defining condition in 37%, median CD4 cell count 658 (IQR 497–814) cells/μl). Overall, 25 (83%) patients were
diagnosed with HIV-associated neurocognitive disorders (HAND) on in-depth neuropsychological assessment
(16 patients had asymptomatic neurocognitive impairment (ANI), 8 a mild neurocognitive disorder (MND) and 1
patient HIV-associated dementia (HAD). Among 25 patients with HAND, only 9 patients (36%) were complaining of
memory loss. The screening battery revealed neurocognitive deficits in 17 (57%) patients (sensitivity 64%, specificity
80%, positive predictive value 94% and negative predictive value 31%). Most patients (83%) estimated the screening
test as valuable and not worrisome.
Conclusions: A questionnaire combined with selected neuropsychological tests is a short, easy-to-perform very well
accepted screening tool for mild neurocognitive disorders in asymptomatic HIV-infected individuals.Background
Combined antiretroviral therapy (cART) has dramatic-
ally changed the prognosis of HIV-infection (Mocroft
et al. 2003; Weber et al. 2012; Stöckle et al. 2012; Jaggy
et al. 2003; Egger et al. 2002). Given a timely diagnosis
and treatment, life expectancy is most likely only mar-
ginally decreased compared to the general population
(The Antiretroviral Therapy Cohort Collaboration 2008).
Therefore, with increasing age of HIV patients, long-term
aspects such as neurotoxic effects of the virus and possibly
of treatments gain importance (Robertson et al. 2009).
Losses in memory function, psychomotor speed and/or
executive functions may occur at a higher frequency in
HIV-infected compared to HIV-negative individuals
(Robertson Robertson et al. 2009). Cognitive disorders may
negatively impact behaviour (Hinkin et al. 2002), autonomy* Correspondence: manuel.battegay@usb.ch
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reproduction in any medium, provided the orin everyday life, and risk behaviour (Gonzalez et al. 2005;
Vance & Struzick 2007), leading to a diminished quality
of life, lower adherence to cART and increased mortality.
An early diagnosis of cognitive impairment is important for
the initiation of cART which can then lead to improve-
ments of neurocognitive symptoms (Cysique & Brew 2009;
Joska et al. 2010; Tozzi et al. 2007).
Definition of HIV-associated neurocognitive disorders
(HAND) include three conditions: asymptomatic neuro-
cognitive impairment (ANI), HIV-associated mild neuro-
cognitive disorder (MND) and HIV-associated dementia
(HAD). The prevalence of HAND was estimated to be 69%
in HIV-infected persons in Switzerland who have been suc-
cessfully treated for many years (Simioni et al. 2010). In a
US study (Robertson et al. 2007), 21% of asymptomatic
HIV-infected individuals fulfilled the criteria for ANI. Sub-
jective reports about cognitive symptoms seem to be unre-
liable as up to 64% of asymptomatic patients were found
to have cognitive impairment on neuropsychological as-
sessment (Simioni et al. 2010). A patient’s underestimationd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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meta-memory, i.e. an executive dysfunction (Woods et al.
2009). On the other hand, overestimation of one's own
cognitive deficit is frequently seen in patients with de-
pressive disorders (Rourke et al. 1999; Carter et al. 2003).
Various screening tests like the HIV dementia scale (HDS)
(Power et al. 1995), the EXIT interview (Berghuis et al.
1999), the Mental Alternation Test (Jones et al. 1993),
the modified Memorial Sloan-Kettering Scale (Marder et al.
2003) or the International HIV Dementia Scale (IHDS)
(Sacktor et al. 2005) are used to identify HIV associated de-
mentia, but these tests are not sensitive enough to detect
the milder forms of HAND, i.e. ANI and MND, which are
more prevalent in the HIV population (Singh et al. 2010;
Carey et al. 2004). Recently, a score ≤ 14 points on the HDS
(Power et al. 1995) was found to yield a positive predict-
ive value of HAND of 92% in complainers and 82% in
non-complainers (Robertson et al. 2007).
A useful screening test must have acceptable psychomet-
ric properties. Carey et al. (Carey et al. 2004) were able to
show that a combination of only two validated and standar-
dised neuropsychological tests was better at classifying
patients with cognitive disorders than the HDS alone. The
neuropathological changes caused by the HIV infection
mainly affect the fronto-striato-thalamo-cortical circuit, def-
icits in processing speed, executive functions and verbal epi-
sodic memory (Robertson et al. 2009; Woods et al. 2009).
The most frequently used tests which are viewed as sensi-
tive are the verbal memory tasks (Singh et al. 2010; Carey
et al. 2004; Skinner et al. 2009), the Trail Making Test part
A and B (1944; Tombaugh et al. 1998), the Grooved Peg-
board Test (Ruff & Parker 1993), the Digit Symbol Test
(Härting et al. 2000; Aster et al. 2006), and the Digit Span
forwards and backwards (Härting et al. 2000). Combination
of the Hopkins Verbal Learning Test – Revised (HVLT-R)
(Benedict et al. 1998) with the Digit Symbol Test (Härting
et al. 2000; Aster et al. 2006) or with the Grooved Pegboard
Test (Ruff & Parker 1993) non-dominant hand yielded a
sensitivity of 75-78% and a specificity of 85-92%, respect-
ively, in detecting mild cognitive disorders in HIV-infected
individuals (Carey et al. 2004).
Taking the above mentioned findings into account,
the aims of this study were to evaluate the performance
and to assess the acceptability of a German-language
screening battery consisting of a short questionnaire
and seven brief neuropsychological tests administered
by trained nurses to screen for neurocognitive deficits
in treated HIV-infected patients.
Methods
Ethical approval
The protocol was approved by the local Ethics Committee
“Ethikkommission beider Basel”. All patients gave written
informed consent.Study participants
Study participants were 30 HIV-infected individuals in
care at the HIV Clinic of the University Hospital Basel,
Switzerland meeting the following inclusion criteria:
age ≥18 years, cART since ≥6 months, an undetectable
HIV viral load (<50 copies/mL) for ≥3 months, and to
be a German native speaker. Exclusion criteria were audi-
tory, visual or motor deficits, clinical signs of disorienta-
tion, current injecting drug use, current major depression
according to Diagnostic and Statistical Manual of Mental
Disorders (Trull et al. 2012), neurologic or severe psychi-
atric conditions that affect cognition, and a history of op-
portunistic infection of the central nervous system within
the last 2 years. The following data were collected at the
time of the screening test and obtained from the prospect-
ive data collection of the Swiss HIV Cohort Study: age,
education, gender, CDC stage, CD4 cell count, HIV viral
load, co-infection with hepatitis C, co-medication, drug
and alcohol consumption, history for cART, opportunistic
diseases and syphilis. Medical history of thyroid or vitamin
B12 deficiency was not reviewed.
Study procedures and examination tools
Two study nurses were trained by a neuropsychologist
on how to perform the screening battery according to
standard procedures. The screening test consisted of a short
questionnaire and seven selected neuropsychological tests
based on theory-led principles and psychometric criteria,
and it has already proven its value in a similar form in
HIV-infected individuals (Carey et al. 2004). The time
needed to perform the short examination was recorded
and its acceptance was evaluated by a feedback ques-
tionnaire for both patients and nurses.
Screening battery
Our screening battery comprised a questionnaire and a
short examination of selective cognitive functions.
1. Questionnaire
Following questions were asked to investigate cognitive
functions: Do you frequently experience memory loss
(e.g. do you forget the occurrence of special events even the
more recent ones, appointments, etc.)? Do you feel that
you are slower when reasoning, planning activities, or solv-
ing problems? Do you have difficulties in paying attention
(e.g. to a conversation, a book, or a movie)? Patients could
answer with ‘never’, ‘rarely’, ‘sometimes’, ‘often’ or ‘always’.
As individuals may overestimate or underestimate their
own deficits when making subjective statements on cogni-
tive losses (Hinkin et al. 2002), we added two questions to
increase the robustness of the subjective statements: one
on everyday memory complaint because memory losses
are frequently reported in this area (Woods et al. 2009):
Do you intend to do something and then you forget what
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and then forget what you wanted to get)? The second
refers to whether friends or family made remarks on
the individual’s diminished cognitive skills: Do friends
and/or members of your family tell you that your brain
power has deteriorated?
The following two questions were asked to estimate
whether there was a clinically relevant depression
(Sacktor et al. 2005): How often did you note little interest
or pleasure in doing things over the past 2 weeks? How
often did you experience feeling down, depressed or
hopeless over the past 2 weeks? Patients could answer
with ‘not at all’, ‘several days’, ‘more than half the days’
or ‘nearly every day’.
2. Examination of selected cognitive functions
Examination of selected cognitive functions consisted of
seven brief tests to evaluate the following four domains:
cognitive speed, memory, executive functions, and motor
speed (Table 1).
Following the above some tests counted for more than
one domain, e.g., if the result in TMT part A was below
1 standard deviation, it counted in the domains "cognitive
speed" and "motor speed".
The domains were considered as pathological, if one re-
sult in this domain was pathological, ie, a standard score
below −1.0. The cognitive screening was considered patho-
logical if the patient had deficits in two or more domains.
Nurses who administered the screening test were
provided with a table indicating pathological perform-
ance. For example, a TMT part A result of more than
40 seconds from a subject aged between 40 and 49 years
was considered pathological.
Acceptance of the screening battery
A feedback questionnaire was filled out by each patient
and the study nurse to evaluate the acceptance of the
screening test. The questionnaire for patients comprised
the following questions: Is the test too difficult? Are the
instructions clear? Does the test respect your privacy? IsTable 1 List of the seven tests used to evaluate the four do
and motor speed)
Cognitive domain Test
Cognitive speed Trail Making Test (TMT) (1944; Tombaugh et al. 199
Digit Symbol Test (DST) (Härting et al. 2000; Aster
Memory wordlist from the Multiple Sclerose Inventarium Co
(Calabrese et al. 2004)
Executive functions TMT ( 1944; Tombaugh et al. 1998) part A and B
Motor speed DST (Härting et al. 2000; Aster et al. 2006)
Grooved Pegboard (Ruff & Parker 1993) with domi
and non-dominant hand
TMT ( 1944; Tombaugh et al. 1998) part A and Bthe screening reasonable? Is the test burdening? Are you
interested in the results of the examination? Is the test
too long? The questionnaire for study nurses included
following questions: Is the test too difficult for patients?
Is the screening reasonable? Is the test burdening for the
study nurse? Is the test too long?
The patients and nurses could answer on a scale of 1–5
(not at all – totally).
The questionnaire for nurses comprised also the follow-
ing questions: Were there any ambiguities or uncertainties
in the instructions? Were there any ambiguities or uncer-
tainties in the evaluation? Were there any ambiguities or
uncertainties in the interpretation?
The nurses were also able to attach comments or
suggestions.
In-depth neuropsychological assessment
Within one month, study participants were examined at
the Basel Memory Clinic by a neuropsychologist using a
comprehensive test battery to evaluate HAND. The exam-
ining neuropsychologist had no access to the results of the
screening test.
The comprehensive neuropsychological examination,
lasting for two hours, covered the following tasks:
German version of the California Verbal Learning Test
(Delis et al. 1987) (when age ≥ 50 years) or the Verbal
Learning and Memory Test (Helmstadter et al. 2001)
(when age < 50 years); Figural Fluency (Regard et al. 1982),
modified Wisconsin Card Sorting Test (Nelson 1976);
Rey-Osterrieth Complex Figure (Rey 1941); verbal fluency
(semantic and phonemic) (Morris et al. 1989), Color Trails
1 and 2 (D’Elia et al. 1996); Boston Naming Test, 15 items
(Nelson 1976); Digit Span (Härting et al. 2000; Aster
et al. 2006), Color Word Interference Test (Stroop 1935)
and Test of Attentional Performance (divided attention and
alertness) (Fimm & Zimmermann 2009).
Statistical analysis
Basic socio-demographic characteristics, CD4 cell count,
and cART were compared using the Chi-square test ormains (cognitive speed, memory, executive function
Variables
8) part A and B number of seconds to complete part A and part B
et al. 2006) number of correct items
gnition number of correct items on 10 items learning and
delayed recall
number of seconds to complete part B
number of correct items
nant number of seconds needed for completion
number of seconds to complete part A and part B
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Whitney test for continuous variables. All analyses were
performed using STATA software version 11 for Windows
(STATA Corp, College Station, Texas, USA).
Results
A total of 30 patients were included in this study be-
tween January 2011 and July 2011 at the HIV-Clinic of
the University Hospital Basel. The median age was 52.5 years
(interquartile range (IQR) 47–64) and most patients
(87%) were males. One patient had a HIV viral load of
58 copies/mL, another one 65 copies/mL. Five patients
had an elevated HIV viral load (range 86–3594 copies/mL)
within 6 months before this investigation. The median CD4
cell count was 658 cells/μL (IQR 497–814); 11 patients
(37%) had previously been diagnosed with an AIDS-defining
infection, one of these suffering from cerebral toxoplasmosis
12 years before without clinically obvious neurological
sequelae. Among co-morbidities, 3 patients (10%) had co-
infection with hepatitis C, one patient had a history of
transient ischemic attack many years before, and 5 patients
(16.7%) had previously been treated for syphilis (stage I-II).
Lumbar puncture yielding a negative syphilis serology of
CSF was only done in one patient. We did not routinely
carry out a lumbar puncture when patients had no clinical
signs of involvement of the central nervous system
between 6 months and 9 years before this investigation.
Prevalence of HAND
Overall, 25 (83%) patients were diagnosed with HAND based
on in-depth neuropsychological assessments. Of these, 16
patients (64%) had ANI, 8 (32%) MND, and 1 patient HAD.
Among the 25 patients with HAND, only 9 patients (36%)
were complaining of memory loss or difficulties to concen-
trate. The patient with HAD had HIV-infection CDC B3
with no relevant co-morbidity, in particular no obvious
neurological disease. He was treated with an efavirenz-
containing antiretroviral regimen. One of the 8 patients
(13%) with MND and 5 (31%) of the 16 patients with ANI
were also treated with an efavirenz-containing regimen. The
5 patients with a treated syphilis were diagnosed with ANI
(n = 3), MND (n = 1), and no cognitive impairment (n = 1).
ANI was also diagnosed in one patient with stroke and
in another patient with a history of cerebral toxoplasmo-
sis. Also, two patients with occasional drug consumption
(inhalative cocain, ketamin, methadon) had ANI. One
patient with daily cannabis consumption had MND.
Detailed results of the in-depth neuropsychological
examination are shown in Table 2.
Validity of questions addressing subjective cognitive
impairment (SCI)
Twenty-five of the 30 patients were diagnosed with HAND
based on the in-depth neuropsychological assessment.Among those, nine had reported a SCI (ie, sensitivity
of SCI = 36%). Five patients had received a diagnosis of
normal cognition after the in-depth neuropsychological as-
sessment. Two of those had not reported SCI (ie, specificity
of SCI = 40%). Thus, questions addressing SCI did not
separate between those with and those without HAND.
Screening test battery
The screening battery revealed neurocognitive deficits
in 17 of 30 (57%) patients (Figure 1 and Table 3), corre-
sponding to a sensitivity of 64% (95% confidence interval
(CI 42-82%), a specificity of 80% (95% CI 28-99%), a PPV of
94% (95% CI 71-99%) and a NPV of 31% (95% CI 9-61%).
Almost all patients with a pathological screening test
(16/17, 94%) had a pathological result on their neuro-
psychological assessment. However, among the 13 patients
with a normal screening result, 9 (69%) had HAND at
the in-depth neuropsychological examination, i.e. were
false negative. If only non-complaining patients (n = 18)
were considered, i.e. patients not complaining of mem-
ory loss or difficulties in concentrating, the screening
battery yielded a sensitivity of 75% (95% CI 48-93%) and
a specificity of 100% (95% CI 19-100%), a PPV of 100%
(95% CI 73-100%) and a NPV of 33% (95% CI 5-77%). If
only patients with memory loss or difficulties to concen-
trate (n = 12) were considered, the screening battery had
a sensitivity of 44% (95% CI 14-79%), specificity of 67%
(95% CI 12-94%), a PPV of 80% (95% CI 29-97%) and a
NPV of 29% (95% CI 5-71%). If results of the screening test
battery were combined with those of the questionnaire
(either one or both tests positive), a sensitivity of 84%
(95% CI 64-95%), a specificity of 40% (95% CI 6-85%), PPV
of 88% (95% CI 68-97%) and NPV of 33% (95% CI 5-77%)
could be reached.
Comparison of results of the screening battery to those
of the in-depth neurolopsychological assessment are shown
in Table 3 and Figure 1.
Baseline characteristics of the study population accord-
ing to results of the screening battery are shown in Table 4.
Test results were independent from demographic patients’
characteristics, CD4 cell count, co-medication and cART.
The overall duration of the screening test was 25 minutes
(IQR 23–29), shorter if the patient had a normal neuro-
psychological assessment (21 minutes, IQR 20–25).
Acceptance of the screening battery
The overall acceptance of the screening battery was excel-
lent. Most patients (83%) estimated the screening test as
valuable and not worrisome, and were interested in the re-
sults. Most participants (97%) considered the instructions
for the test given by the study nurses as clear and the test
battery as not difficult or partly difficult in 43% and 57% of
patients, respectively. Privacy was not affected by the test
according to 93% of patients, and nobody reported that the
Table 2 Raw scores of the in-depth neuropsychological assessment
Max IQR 25% Median IQR 75% Range
California Verbal Learning Test (n = 18):
Learning (trial 1–5) 80 43 47 54.75 26-63
Short Delay Free Recall 16 7.3 9.5 12.0 1-16
Long Delay Free Recall 16 7.3 11.0 12.0 1-16
Recognition Discriminability (%) 100% 90.9 93.2 95.5 81.2-95.5
Verbal Learning and Memory Test (n = 12):
Learning (trial 1–5) 75 34.8 45.5 51.8 28-66
Delayed Recall 15 7 10 11 2-14
Figural Fluency n.a. 25.3 32.0 36.5 8-57
Modified Wisconsin Card Sorting Test:
Categories 6 6 6 6 1-6
Perseverative Errors n.a. 0.0 0.5 3.0 0-8
Rey-Osterrieth Complex Figure:
Copy 36 29.6 31.8 32.9 18.5-35.0
Immediate Recall 36 12.1 19.0 24.5 2.0-28.5
Delayed Recall 36 10.8 18.5 24.4 3.0-26.5
Semantic Fluency (Animals), 1’ n.a. 16.5 21 24 12-33
Phonemic Fluency (S-Words), 1’ n.a. 9 12 16 6-19
Color Trails 1 240“ 33 37 49.75 19-126
Color Trails 2 240“ 0 0 1 0-6
Boston Naming Test 15 14 15 15 11-15
Digit Span forward 12 6 7 8 4-11
Digit Span backward 12 5 5.5 6 2-10
Color Word Interference Test Time 1 (s) n.a. 12 13 15 10-22
Color Word Interference Test Time 3/1 n.a. 1.85 2.17 2.40 1.53-3.76
Test of Attention Performance:
Divided Attention Auditive (ms), Median n.a. 516 555 631 329-1109
Divided Attention Visual (ms), Median n.a. 758 830 898 599-1234
Alertness (ms), Median n.a. 221 237 286 186-634
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battery as not too difficult for patients, valuable and not
worrisome, and not too long.
Discussion
In this study, investigating a specific combination of tests
comprising a short questionnaire and a battery of selected
neuropsychological tests for mild neurocognitive deficits
in 30 HIV-infected individuals receiving cART, we found a
moderate sensitivity and specificity when comparing to the
in-depth neuropsychological examination serving as the cri-
terion standard. Importantly, we found a high acceptance
rate by patients and nurses. The sensitivity and specificity
for this screening battery was increased in patients not
complaining of memory loss or difficulties in concentration.
If we combined results of the screening battery with those
from the questionnaire (either one or both tests positive)we reached a sensitivity of 84% with a PPV of 88% and a
NPV of 33%, making this screening strategy, administered
by nurses, a simple, well accepted tool to screen treated
HIV-infected individuals for mild neurocognitive disorders.
The prevalence of HAND in our study population
was high (83%). This is in agreement with other studies
(Simioni et al. 2010). This is remarkable since all patients
were not of older age, had no major psychiatric diseases
and were not currently injecting drug users. Also, almost
all patients had experienced a long school and professional
education. Furthermore, nearly all patients had a sup-
pressed viral load and were immunologically stable
under continuous cART.
We consider the two viral load measurements in two
patients (58 copies/mL and 65 copies/mL, respectively) as
technical blips, however, we cannot rule out a low level





















Figure 1 Performance of the screening battery according to the presence of HAND at the in-depth neuropsychological examination.
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this investigation. The patient with 3594 copies/ml did
not take his medication at this time. Within the last
3 months before the examination, however, the viral
load was suppressed.
Importantly, we could neither find any association
with a cART regimen, in particular with efavirenz-based
cART, nor with co-morbidities possibly affecting the neu-
rocognitive performance. Interestingly, objective evidence
of HAND was slightly more frequent in patients without
complaints suggesting that an easy screening tool is
very valuable before neuropsychological examination with
more sophisticated instruments. Complaints about memory
loss and difficulties to concentrate are difficult to interpretTable 3 Performance of the screening battery according to














25 5 30and also frequently reported by HIV-negative individ-
uals (20-70%) without objective cognitive impairment
(St John & Montgomery 2002; Reid & Maclullich 2006).
One of the problems encountered with investigating a
new screening battery is the lack of a clear criterion stand-
ard. However, the in-depth neuropsychological examination
has been well validated for cognitive assessment. The
search for a good, easy-to-perform screening test is still
justified, as the international HDS (Sacktor et al. 2005)
and the HDS (Power et al. 1995) that are widely used as
screening tests to identify individuals at risk for HAD
(Sacktor et al. 2005), are not enough sensitive to detect
mild forms of neurocognitive deficits. However, the HIV
dementia scale with a cut-off of 14 points was shown to
have a sensitivity of 83%, specificity of 63% and a PPV of
92% to detect HAND in patients with complaints and a
sensitivity of 88%, specificity of 67% and PPV of 82% in
non-complaining patients (Simioni et al. 2010). As a
preliminary but encouraging result of this pilot study,
our screening battery showed a similar accuracy as the
HDS. An advantage may be that our screening battery
does not comprise the anti-saccadic eye movement task,
which can be challenging for the examiner. In addition
to using cognitive tests only it incorporates the informa-
tion about the patient's subjective cognitive impairment.
Importantly, our approach to improve the screening for
HAND requires a great deal of further work. In line with
the suggestions outlined by Kamminga et al. (2013), at least
the following points need to be addressed: (a) use of a rep-
resentative sample of the HIV population, (b) inclusion of a
Table 4 General characteristics of the study population (n = 30) according to results of the screening battery
Pathological screening
test N = 17
Normal screening
test N = 13
p-value
n % n %
Median Age, IQR 55 49-64 49 43-61 0.201
Males 15 88 11 85 0.591
Prior AIDS-defining condition 6 35 5 38 0.579
Median CD4 cell count, IQR 565 405-738 695 531-891 0.187
Median years of education, IQR 12 11-13 13 12-13 0.336
cART containing efavirenz 6 35 2 15 0.212
Co-medication with psychotropic drugs (antidepressants, antipsychotics) 5 29 2 15 0.427
Memory loss or difficulties to concentrate reported by the patient* 5 29 7 54 0.164
Depressive symptoms* 2 12 1 8 0.603
Median duration of screening battery, minutes, IQR 25 25-29 23 21-26 0.099
*According to the questionnaire.
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mally assess HAND specificity, (c) a more explicit rationale
for screen impairment criteria, (d) reporting of all standard
criterion validity indexes, (e) reporting of construct validity,
and (f) assessing the longitudinal validity of the screening
tool including correction for practice effects. Moreover, ac-
ceptability was excellent by patients and nurses.
We acknowledge some limitations: First, the number
of patients was too small to draw conclusions regarding
specific associations for neurocognitive deficits and cART
regimen, e.g. efavirenz-based treatment that may impact
on the central nervous system, or specific co-morbidities.
Second, we did not perform MRI examinations of the
brain nor lumbar punctures to exclude other causes of
neurocognitive impairment than HIV. Third, the HIV
dementia scale (Sacktor et al. 2005) was not performed
in our study population, so that a direct comparison
with our screening test was not possible. Forth, the use of
the same variable to assess different cognitive domains is
problematic. This variable receives an unjustified import-
ance and may lead to invalid results. Furthermore, combin-
ing the results of a screening battery with a questionnaire
for subjective cognitive impairment is not in line with the
Frascati criteria (Antinori et al. 2007). However, this more
comprehensive screening approach will allow the medical
staff to detect not only patients with HAND, but also
others, who might be in need of medical care, which in
our view is an advantage.
In our study the prevalence of HAND was high. This
may be due to the fact that patients with HCV co-infection,
history of ischemic stroke, drug use and previous cerebral
opportunistic infections were included in this study.
Drug use was assessed by self-report. We acknowledge
self-report and potential interference of drug use as a
limitation. Future research should also exclude patients
with occasional drug consumption.This study also has several strengths: First, this is the
first study investigating a short screening battery with
selected neuropsychological tests that were adminis-
tered by nurses. Second, all 30 patients were under-
went comprehensive neuropsychological assessments.
Third, the fact that all patients were participating in
the prospective Swiss HIV Cohort Study enabled us to
assess important co-morbidities such as depression or
syphilis and the corresponding treatments.
Conclusion
In conclusion, our study demonstrates that screening for
neurocognitive deficits is likely to identify milder forms of
cognitive disorders even in non-complaining patients. A
short questionnaire combined with a small battery of se-
lected neuropsychological tests is a short, easy-to-perform
screening tool for HIV-infected individuals.
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